CBLL · CeriBell, Inc. — research history
Complete research history. Every dossier, draft, kill, publish, and lesson the system has produced on CBLL. Public so users can audit, AI can re-reference. Live price refreshes every 60s.
About CBLL · CeriBell, Inc.
CeriBell, Inc. operates as a medical technology company in the United States. It develops the Ceribell System, a novel and point-of-care EEG platform specifically designed to address the unmet needs of patients in the acute care setting. The company also offers disposable, flexible headbands, and headcaps; and a pocket-sized, rechargeable battery-operated recorder used to capture and wirelessly transmit EEG signals; and Clarity, an AI-powered seizure detection algorithm. In addition, it operates an EEG portal, which enables real-time remote access to a patient's EEG data. The company was formerly known as Brain Stethoscope, Inc. and changed its name to CeriBell, Inc. in August 2015. CeriBell, Inc. was incorporated in 2014 and is headquartered in Sunnyvale, California.
Live Quote
HOLD (score +3) · 12-1 mom -4.6% · RSI 50.7 · above_200_only · -21.5% from high
Targets blend Wall Street consensus (7 analysts: low $24.00 / mean $26.86 / high $32.00) with chart-derived floors and ceilings.
1-Year Chart · RSI · MACD
Research Timeline
Newest first. Each entry shows what stage produced it, the verdict/decision, and the reasoning.
CeriBell is an early-commercial medical device company with 29% YoY revenue growth ($26.5M in Q1 2026), 87.7% gross margins, and a point-of-care EEG platform that holds first-in-class FDA clearances for seizure detection (Clarity) and delirium monitoring. The stock is up ~66% YTD following a strong earnings beat on May 11 where full-year guidance was raised and Q1 new hospital adds were the strongest since IPO. However, critical analysis of all four June-4 Form 4 filings reveals they are director RSU vesting grants (Code A at $0) — NOT open-market purchases — and the investigation trigger requirement of 'at least one verified open-market P/S trade' is not satisfied. The CEO's recent transactions were selling via pre-scheduled Rule 10b5-1 plans; no insider has made a discretionary open-market purchase in this period. At forward P/E negative, deeply loss-making, with Q2 earnings not until August 4, the stock lacks both the mispricing and genuine smart-money clustering needed for an asymmetric long thesis.